Seahorse XF96 Extracellular Flux Analyzer Wins Best New Product Award for DRUG DISCOVERY...

Seahorse XF96 Extracellular Flux Analyzer Wins Best New Product Award for DRUG
DISCOVERY at 2009 Molecular Medicine Conference

BILLERICA, Mass., March 12 /PRNewswire/ -- Seahorse Bioscience, Inc., leader
in the real-time measurement of cellular bioenergetics, announced today that
the XF96 Extracellular Flux Analyzer, the first analytical instrument for the
kinetic measure of mitochondrial oxygen consumption and cytoplasmic glycolysis
in a 96-well microplate, was selected as the Best New Product for Drug
Discovery Assays & Kits by researchers at the Molecular Medicine
Tri-Conference in San Francisco.

"The XF96 Analyzer has revolutionized the way we approach toxicity screening,"
said Yvonne Will of Pfizer's Compound Safety Prediction Group, who spoke about
mitochondrial toxicity at the conference and one of the first users of the
XF96. "Since getting the high throughput capabilities of the XF96 Analyzer,
we routinely generate 6 point cellular bioenergetic EC50's on our drug
candidates - something that just wasn't possible before."

XF Analyzers enable researchers to simultaneously measure the two major
energy-producing pathways of the cell in real-time, delivering easy-to-use,
information-rich bioenergetic assays to study and develop treatments for
obesity, diabetes, ageing and cancer, and to screen for mitochondrial
toxicity.

The XF96 Analyzer offers the distinct advantage of making it possible to
perform these complex bioenergetic assays in a 96-well microplate. XF
Analyzers replace Clark-type electrodes, oxygen or pH sensitive dyes, and
radiolabeled substrates.

"Prior to the introduction of our XF instruments the standard method for
oxygen measurements was using a Clark electrode, invented in 1953, and a flask
of millions of cells," stated Steve Chomicz, Seahorse VP Sales & Marketing.
"The XF is the new standard and this award mirrors the positive response we
experience everyday from researchers struggling to measure cellular
bioenergetics. Seahorse and the XF development team are delighted with CHI's
recognition of the value of the XF platform."

About Seahorse Bioscience
Seahorse XF instruments have become the new standard in cellular bioenergetic
measurements. Scientists worldwide use these tools to advance their research
in understanding the role of mitochondrial function in obesity, diabetes,
ageing, cancer, cardiovascular function and safety toxicity. Founded in 2001,
Seahorse is headquartered in Billerica, MA. For more information, please
visit http://www.seahorsebio.com.

Media Contact: Cynthia Egan
Phone: 978.671.1610

SOURCE Seahorse Bioscience, Inc.

Media, Cynthia Egan of Seahorse Bioscience, Inc., +1-978-671-1610